ZOLGENSMA (onasemnogene abeparvovec-xioi)
Condition : New
0
From UAE
To United States
in 5-10 days
Description
How It Works
Zolgensma works by delivering a functional copy of the SMN gene into the patient’s cells using a viral vector called adeno-associated virus 9 (AAV9). This vector targets motor neuron cells and introduces the healthy SMN gene, which then produces the survival motor neuron (SMN) protein. This protein is essential for the maintenance and function of motor neurons, and its presence helps to improve muscle function and slow the progression of SMA.Side Effects
- Elevated liver enzymes
- Nausea and vomiting
- Decreased platelet count (thrombocytopenia)
- Fever
- Decreased appetite
- Elevated cardiac troponin-I
Indications
- Treatment of spinal muscular atrophy (SMA) in pediatric patients under the age of 2 with bi-allelic mutations in the SMN1 gene
Contraindications
- Hypersensitivity to any of the components of Zolgensma
- Patients with advanced liver disease
- Severe pre-existing thrombocytopenia
Price Comparison in Different Countries
Country | Price | Reference |
---|---|---|
Pakistan | Approximately PKR 250,000,000 | Dawaai Pakistan |
United States | USD 2,125,000 | GoodRx |
United Kingdom | GBP 1,795,000 | NHS UK |
Canada | CAD 2,850,000 | Health Canada |
Australia | AUD 2,900,000 | PBS Australia |
Top 5 Global Brands
- Novartis
- Pfizer
- Roche
- Sanofi
- GlaxoSmithKline (GSK)